Loading clinical trials...

A Study of Olezarsen Administered Subcutaneously to Participants With Severe Hypertriglyceridemia | Clinical Trials | Clareo Health

Back to clinical trial search

COMPLETEDPhase 3NCT05552326

A Study of Olezarsen Administered Subcutaneously to Participants With Severe Hypertriglyceridemia

The purpose of this study is to evaluate the efficacy of olezarsen as compared to placebo on the percent change in fasting triglycerides (TG) from baseline.

Lead sponsor: Ionis Pharmaceuticals, Inc.•63 U.S. locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Clareo turns complex medical information into clear understanding you can use.

Bring this clarity to your next appointment.

Keep all your medical notes and next steps in one place.

Start Free Trial

Related studies

COMPLETEDPhase 2

Safety and Efficacy Following Repeat-Dose of Evinacumab (Anti-ANGPTL3) in Patients With Severe Hypertriglyceridemia (sHTG) at Risk for Acute Pancreatitis

NCT03452228 · Severe Hypertriglyceridemia (sHTG)

WITHDRAWNPhase 3

The Efficacy of EPA+DHA (SC401B) for Lowering Triglyceride Levels (≥ 500 mg/dL)

NCT01997268 · Severe Hypertriglyceridemia

COMPLETEDPhase 2/3

Epanova® for Lowering Very High Triglycerides

NCT01242527 · Severe Hypertriglyceridemia

UNKNOWNPhase 3

Efficacy Study to Treat Subjects With Severe Hypertriglyceridemia

NCT01229566 · Severe Hypertriglyceridemia

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: October 22, 2025Terms

Trial snapshot

StatusCOMPLETED

PhasePHASE3

Enrollment446

Start dateAug 2022

Last updatedOct 22, 2025

Condition

Severe Hypertriglyceridemia

Locations shown

Central Research Associates, Inc.

Birmingham, Alabama

Alabama Clinical Therapeutics, LLC Alabaster

Birmingham, Alabama

Onyx Clinical Research

Peoria, Arizona

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: October 22, 2025Data synced to Clareo: May 10, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions